For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important ...

CAMBRIDGE, Mass., Oct. 29, 2025 /PRNewswire/ -- CREATE Medicines, Inc. (formerly Myeloid Therapeutics) today announced new preclinical data for RetroT, the company's fully RNA-encoded, site-specific ...

LONDON and CHICAGO, Dec. 15, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) ...

Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies. High transgene expression and improved safety profile of Aldveron's ...

Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...

Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...

Researchers have unlocked a way to grow the immune system’s “conductors” from stem cells, bringing ready-made cancer-fighting therapies a big step closer. For the first time, scientists at the Univers ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid ...

Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, or CAR-T cell therapy. Over time, the engineered immune ...